Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Reported Saturday, IO Biotech Announced Data From Phase 2 Basket Trial Of IO102-IO103, Therapeutic Cancer Vaccine Candidate, In Combination With Merck's Keytruda At The 2024 ESMO Congress

Author: Benzinga Newsdesk | September 16, 2024 04:42am

Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma of the Head and Neck Cohort.
No New Safety Signals or Added Systemic Safety Concerns Observed

Posted In: IOBT